Night sweats
Conditions
Interventions
Experimental group:Take 100mg of thalidomide orally every night before bedtime.
Sponsors
Nanjing BenQ Mecical Center
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Pancreatic cancer chemotherapy patients presenting with night sweats; 2.Aged between 18 and 80 years; 3.Individuals who provide informed consent to participate in the study and cooperate with follow-up.
Exclusion criteria
Exclusion criteria: 1.Children; 2.Pregnant women or women of childbearing potential not using reliable contraception; 3.Lactating women (or Breastfeeding women); 4.Patients with an absolute neutrophil count (ANC) <=750/mm^3; 5.Patients already using thalidomide analogues or other anti-anhidrotic medications; 6.Patients with a history of seizures or other risk factors for seizure disorders; 7.Patients with tuberculosis, HIV-positive status, or a history of such infections; 8.Patients without fever or symptoms of acute infection and in whom medication review reveals no identifiable cause for night sweats; 9.Individuals who decline to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Night Sweats Response Rate;Drug safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival (OS);Improvement in quality of life (QoL); | — |
Countries
China
Contacts
Public ContactJing Zhu
Nanjing BenQ Mecical Center
Outcome results
None listed